Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC

NCT03219762 ↗

Phase 2 Unknown 65 enrolled Italian Oncology Group for Clinical Research Clirest s.r.l. · collab Istituto Toscano Tumori · collab Mipharm S.p.A. · collab Temas srl · collab

NaSingle-groupOpen-labelHealth-services research

Summary

Evaluate the activity and safety of Nab-paclitaxel in patients with sensitive or refractory SCLC who relapsed after cisplatin or carboplatin and etoposide first-line chemotherapy.

Timeline

Start: 2017-02-07
Primary completion: 2019-01
Completion: 2019-01

Outcome

Missed primary endpoint

paper the primary end-point of the study was not met. PMID 32346071 ↗

Publications

Gelsomino F, Tiseo M, Barbieri F, Riccardi F, Cavanna L, Frassoldati A, Delmonte A, Longo L, Dazzi C, Cinieri S, Colantonio I, Sperandi F, Lamberti G, Brocchi S, Tofani L, Boni L, Ardizzoni A. Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). Br J Cancer. 2020 Jul;123(1):26-32. doi: 10.1038/s41416-020-0845-3. Epub 2020 Apr 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nab-paclitaxel	Small molecule	100 mg/m2	—